Other denominations
Pharmacological watchdog; pharmacovigilance.
Description
Drugs that reach the market previously pass through exhaustive efficacy and safety studies (pre-clinical and clinical trials). However, there are adverse reactions to drugs which, because of their low incidence in the general population or because they occur in special population groups (children, elderly, pregnant women, etc.), were not detected during the pre-marketing study period. This is why pharmacovigilance, defined by the WHO as "the science and activity related to the detection, evaluation, understanding and prevention of adverse drug effects or any other drug-related problem". is required. The information regarding the side effects of a drug can come from patients, physicians or pharmacists, and is collected on yellow cards. A negative report may result in modification of the summary of product characteristics and use may be restricted or completely forbidden. Pharmacovigilance is mandatory, as it avoids costly errors that could put public health, and the reputation of the company manufacturing or marketing pharmaceuticals, at risk. The person in charge of pharmacovigilance is responsible for the follow-up of the adverse effects of drugs, determine their frequency, seriousness, and incidence, and predict their appearance during the life cycle of the product, from investigation to marketing. They are also responsible for communication with competent authorities.
Tasks
© Barcelona Activa 2023
Centre per al desenvolupament professional Porta22
Barcelona Treball (Porta22)
Llacuna, 156-162, 08018 Barcelona
bcn.cat/treball
Monday to Friday from 9 to 18 h